Millennium Management LLC Acquires Shares of 20,761 GH Research PLC (NASDAQ:GHRS)

Millennium Management LLC acquired a new stake in GH Research PLC (NASDAQ:GHRS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,761 shares of the company’s stock, valued at approximately $145,000.

A number of other hedge funds also recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in shares of GH Research during the fourth quarter worth approximately $44,000. AdvisorShares Investments LLC increased its position in GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock worth $252,000 after buying an additional 4,806 shares during the period. Northern Trust Corp lifted its holdings in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after buying an additional 8,641 shares in the last quarter. Lynx1 Capital Management LP lifted its holdings in shares of GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after buying an additional 663,100 shares in the last quarter. Finally, Diadema Partners LP bought a new stake in shares of GH Research in the fourth quarter valued at about $711,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Trading Down 7.0%

Shares of GHRS opened at $12.83 on Friday. The firm’s fifty day simple moving average is $10.66 and its two-hundred day simple moving average is $10.35. GH Research PLC has a 12 month low of $6.00 and a 12 month high of $20.50. The stock has a market capitalization of $667.52 million, a P/E ratio of -16.24 and a beta of 0.97.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.42. As a group, research analysts predict that GH Research PLC will post -0.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of GH Research in a research note on Friday, May 9th. Stifel Nicolaus upped their price objective on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Cantor Fitzgerald began coverage on shares of GH Research in a research report on Wednesday, June 4th. They issued an “overweight” rating and a $25.00 target price for the company. Wall Street Zen lowered shares of GH Research from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Finally, Guggenheim lowered their price objective on shares of GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, GH Research has an average rating of “Moderate Buy” and an average target price of $32.00.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).